Callan JMB; Chief Medical Officer David J. Croyle acquires 10,195 common shares valued at $17,841

Top Executive Makes Bold Insider Move at Callan JMB, Inc.

Callan JMB, Attune Biotech partner for clinical trials for lodonal

Callan JMB Inc. partners with Attune Biotech to oversee lodonal IND manufacturing and quality control

Callan Jmb Inc. to Oversee Manufacturing and Quality Control of Attune Biotech’s Ind Clinical Trials for Lodonal™ in the Treatment of Long Covid

Callan JMB CEO Wayne Williams to Attend 50th International GMP Conference

Callan JMB to Participate in iAccess Alpha Virtual Best Ideas Spring Investment Conference

NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 10:36 AM

Callan JMB Inc. to Present at DealFlow Discovery Conference

NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:55 AM

Top Premarket Decliners

Callan JMB Stock (CJMB) Rockets 260% on Attune Biotech Deal

Callan JMB Signs $50–$75 Million Manufacturing Oversight and Deployment Agreement with Attune

Callan JMB Signs Manufacturing Oversight, Federal Deployment, and Commercialization Agreement of Multi-Asset Therapeutic Pipeline with Attune for Approximately $50 to $75 Million in Total Revenue

Callan JMB announces strategic pivot to cold-chain infrastructure

Callan JMB Inc. Announces Plans to Expand Cold-Chain Infrastructure and Retrofit Texas Facility to Support Growth in GLP-1 Pharmaceutical Distribution

Callan JMB Inc. Held Annual Shareholder Meeting

Wayne D. Williams, CEO of Callan JMB Inc., Reports Acquisition of Common Shares

Director Duke Liberty Smith acquires common shares of Callan JMB Inc

Callan Jmb Inc - Appoints Christopher Shields as Interim CFO - SEC Filing